

# Xipere (triamcinolone acetonide injectable suspension)

Override(s)	Approval Duration
Prior Authorization	1 month

Medications	Dosing Limit
Xipere (triamcinolone acetonide injectable suspension) 40 mg/mL vial for suprachoroidal use	4 mg (1 single-dose vial) per eye per treatment; repeat treatments may be approved no sooner than 12 weeks after the prior dose.

## **APPROVAL CRITERIA**

Requests for (triamcinolone acetonide injectable suspension) for suprachoroidal use may be approved if the following criteria are met:

- I. Individual has a diagnosis of noninfectious uveitis; **AND**
- II. Individual has evidence of macular edema secondary to uveitis

Requests for Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use may not be approved for the following:

- I. Individual has active or suspected ocular or periocular infections including most viral diseases of cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal disease; **OR**
- II. When the above criteria are not met and for all other indications.

## **Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 2, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
5. Yeh S, Khurana RN, Shah M, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. *Ophthalmology* 2020 Jul;127(7):948-955.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.